Moreover, we used ICD-related genes (CD1A, TSLP, CD36, TIMP1, MC1R, and NRG1) to construct and validate a prognostic risk signature of CRC; patients with low-risk scores had longer OS and might benefit from immunotherapy more than those with high-risk scores. This evidence concerns the gene TSLP and colorectal carcinoma.